Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

CD73 + adipose-derived stem cells reduce scar formation through PLOD1.

Xu M., Fang S., Ma X.

Laboratory Study on Chronic Wound, Scar, published in Ann Transl Med (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Ann Transl Med (2022)
Country
China
Reported sample size
—
Source database
PubMed
PMID
35282129
PMCID
PMC8848413
DOI
10.21037/atm-21-6557
Citations
4

Abstract (original English)

Background Reducing cutaneous scar formation is important for assessing the success of skin wound healing. Although it is generally accepted that adipose-derived mesenchymal stem cells (AMSCs) have substantial therapeutic potential, efforts are continuously made to improve the outcome of AMSC therapy. Post-transcriptional suppression of procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 (PLOD1) in AMSCs has been shown to greatly reduce scar formation during skin wound healing, likely through modulating macrophage polarization. In the present study, we tested whether a CD73 + subpopulation of AMSCs could reduce scar formation compared with CD73 - AMSCs. Methods The gene profile of CD73 + versus CD73 - AMSCs was obtained from a validated public database, GSE167219. AMSCs were isolated from adipose tissue surrounding the groin of mice, after which CD73 + versus CD73 - AMSCs were sorted using flow cytometry. PLOD1 levels were determined in CD73 + versus CD73 - AMSCs. Then, PLOD1 in CD73 - AMSCs was depleted by a short-hair interfering RNA against PLOD1 (sh-PLOD1), while PLOD1 in CD73 + AMSCs was increased by expression of a PLOD1 transgene. A blade was used to induce a skin injury on the middle back of the mice. Either CD73 + AMSCs or CD73 + PLOD1 AMSCs or CD73 - AMSCs or CD73 - sh-PLOD1 AMSCs were intravenously transplanted into the injured region of the mice. Fibrosis and the u

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research